Forty Seven Revenue and Competitors

Location

$156M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Forty Seven's estimated annual revenue is currently $7.4M per year.(i)
  • Forty Seven received $75.0M in venture funding in October 2017.
  • Forty Seven's estimated revenue per employee is $676,364
  • Forty Seven's total funding is $156M.

Employee Data

  • Forty Seven has 11 Employees.(i)
  • Forty Seven grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$1.1M70%N/AN/A
#4
$2.3M15150%N/AN/A
#5
$1.4M90%N/AN/A
#6
$11.5M74-12%N/AN/A
#7
$0.4M27510%$236.7MN/A
#8
$4M51-74%$160MN/A
#9
$2.5M1633%N/AN/A
#10
$3.3M21-12%N/AN/A
Add Company

With a passion for helping patients defeat their cancer, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.

keywords:N/A

$156M

Total Funding

11

Number of Employees

$7.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Forty Seven News

2022-04-20 - Lottery State-by-State-All

(fifteen, sixteen, twenty-two, twenty-three, twenty-seven) ... (seven, eleven, thirty-six, forty-three, forty-six, fifty; Extra Shot: five).

2022-04-20 - Winning numbers drawn in ‘Keno’ game

... twenty-seven, thirty-three, thirty-seven, forty-four, forty-five, forty-seven, forty-eight, fifty-two, fifty-four, fifty-eight,...

2022-04-20 - Winning numbers drawn in 'Pick 10' game

(three, five, six, seven, twelve, eighteen, nineteen, twenty-three, ... thirty-three, forty-three, forty-six, forty-seven, fifty-seven,...

2020-03-21 - Gilead To Buy Forty Seven, for $4.9 Billion

Gilead Sciences, Inc. (Nasdaq: GILD) is to acquire Forty Seven, Inc. (Nasdaq: FTSV), a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University, for $9 ...

2020-03-02 - Gilead to buy cancer immunotherapy company Forty Seven for $4.9B

Forty Seven’s lead product candidate is magrolimab, a monoclonal antibody targeting the cell-surface protein CD47 in Phase Ib development for blood cancers like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and diffuse large B-cell lymphoma (DLBCL). “This agreement builds on Gile ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M11-48%N/A
#2
$2.1M11-27%N/A
#3
$1M11-27%N/A
#4
$2.8M11-48%N/A
#5
$1.7M11-8%N/A

Forty Seven Funding

DateAmountRoundLead InvestorsReference
2016-02-25$75.0MALightspeed Venture PartnersArticle
2017-10-18$75.0MBWellington Management Company LLPArticle